ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 101 participants.

Also called NCT03517436

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03517436
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03517436. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-18 (actual); primary completion 2020-10-02 (actual). Results posted on 2021-09-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
Condition
Aortic Valve Stenosis
Intervention (Device)
TAVR (transcatheter aortic valve replacement) with CENTERA THV
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct03517436
Content hash
6b59d5b1e5493ba5322ad8ee3183236f56537e71498f541137a5053f58dd1c29